PLPiotr Leszczyński

Piotr Leszczyński

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piotr Leszczyński has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnosis and treatment of osteoporosis: 2026 recommendations of the Polish Society for Rheumatology

    by Piotr Leszczyński, Cezary Iwaszkiewicz, Zbigniew Michał Żuber, Brygida Kwiatkowska, Bogdan Piotr Batko, Katarzyna Krystyna Pawlak-Buś

    This publication presents the official recommendations of the Polish Society for Rheumatology for the diagnosis and treatment of osteoporosis. A panel of 6 experienced rheumatologists developed the document using an evidence-informed consensus process incorporating current evidence, clinical experience and the Polish healthcare context. Unanimous agreement was reached on all recommendations. The diagnostic section outlines the diagnostic criteria for osteoporosis in different patient groups and defines, for the first time, the role of radiofrequency echographic multi-spectrometry in clinical practice. The therapeutic section provides guidance on the optimal use of anti-osteoporotic drugs, including sequential therapy, and highlights the benefits of initiating treatment with an anabolic agent in patients at very high fracture risk. The document also addresses prevention of glucocorticoid-induced osteoporosis, osteoporosis in premenopausal women, and diagnosis and treatment in the paediatric population. These recommendations are intended to support early diagnosis and effective management of osteoporosis in Poland.


  • Open Access

    Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab

    by Julia Kołodziejczyk, Izabella Ławińska, Wiktor Schmidt, Piotr Leszczyński, Katarzyna Pawlak-Buś

    Chronic intestinal pseudo-obstruction (CIPO) is an infrequent and menacing complication of systemic sclerosis (Ssc). While researchers report positive impact of rituximab (RTX) on CIPO in paraneoplastic syndrome, no case reports exist for SSc-associated CIPO. The aim of this case-based review is to analyses current literature in context of particular CIPO case description. This analysis was based on PubMed/MEDLINE database and was conducted using the selected key terms. Finally 40 studies/case reports and one case description from authors clinical experience were included into comparison and discussion. As conclusion description of successfuly treatment with RTX and intravenous immunoglobulins can confirm the suggestions from other studies that B-cells participate in the pathogenesis of SSc, making RTX a potentially effective therapeutic option also in coexisting CIPO.


  • Open Access

    Clinical expert statement on osteoarthritis: diagnosis and therapeutic choices

    by Piotr Leszczyński, Przemysław Lisiński, Brygida Kwiatkowska, Tomasz Blicharski, Jarosław Drobnik, Katarzyna Krystyna Pawlak-Buś

    Osteoarthritis (OA) is a chronic, progressive disease that affects bones and joint structures. Osteoarthritis is associated with joint pain, cartilage degradation, synovial inflammation, subchondral bone remodeling and osteophyte formation. It mainly impacts the knees, hips, hands, and lumbar spine. Despite its high prevalence, no current treatments can modify the course of OA, with most therapies focused on symptomatic relief. Non-pharmacological approaches such as weight management, exercise, and self-management programs are strongly recommended. Non-steroidal anti-inflammatory drugs (NSAIDs), both topical and oral, are commonly used but pose risks with long-term use. In contrast, symptomatic slow-acting drugs for OA, such as glucosamine, chondroitin, and avocado-soybean unsaponifiables (ASU), offer a safer alternative, but their effects remain controversial. Newer therapies, including intra-articular glucocorticosteroids, hyaluronic acid, and centrally acting agents such as duloxetine, offer targeted relief. Emerging evidence suggests that ASU may help reduce pain and improve joint function, potentially lowering the need for NSAIDs, with minimal side effects.


  • Open Access

    Protocol for the development of Polish clinical guidelines for the management of patients with systemic lupus erythematosus

    by Joanna Makowska, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko, Marcin Stajszczyk, Jerzy Świerkot, Zbigniew Żuber, Piotr Leszczyński, Agata Sebastian, Magdalena Władysiuk, et al.

    Introduction: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease that causes multi-organ inflammation and damage. Left untreated or inadequately managed, SLE can lead to severe organ dysfunction, disability, and reduced quality of life. In Poland, the absence of standardized, evidence-based clinical guidelines tailored to local resources and practices has created inconsistencies in SLE management. The purpose of these guidelines is to provide clear, evidence-based recommendations for the treatment and management of adult patients with SLE in the Polish healthcare system. These recommendations aim to align clinical practices with international standards, optimize treatment strategies, standardize patient care, and improve health outcomes while guiding healthcare policy.Material and Methods: The adaptation process follows the ADAPTE Collaboration guidelines, the GRADE methodology, and the Evidence to Decision (ETD) framework. An interdisciplinary Working Group (WG), comprising experienced rheumatologists, organ-specific specialists, young rheumatologists, and a patient representative, will develop the guidelines. Key steps will include: 1) creation of clinical questions using the PICO format; 2) systematic search of relevant international guidelines (EULAR, ACR) and national sources; 3) evaluation of identified guidelines using the AGREE II instrument to ensure methodological quality; 4) formulation of recommendations through consensus-based discussions, addressing clinical treatment, monitoring, and care organization.Scope and implementation: The guidelines cover pharmacological interventions for SLE, including hydroxychloroquine, glucocorticosteroids, immunosuppressive drugs biologics. Specific focus areas include treatment of organ-specific manifestations, management during pregnancy, treatment of disease flares, maintenance therapy, monitoring, and comorbidity management. The finalized document will undergo external review and be published in both Polish (on the Polish Society for Rheumatology website) and English (in the journal Reumatologia) as open access. Implementation strategies will include dissemination through scientific journals, presentations at conferences.Conclusions: These guidelines aim to provide a standardized framework for SLE management in Poland. By implementing evidence-based recommendations, they will support healthcare providers in improving patient outcomes, optimizing resource allocation, and addressing the unique challenges of SLE within the Polish healthcare system.

  • The Significance of Vitamin D in Adult Orthopaedics and Traumatology

    by Cezary Iwaszkiewicz, Piotr Leszczyński

    This review summarises the most recent data on the clinical significance of vitamin D in adult orthopaedics and traumatology. It covers practical aspects of vitamin D supplementation, along with their pathophysiological and epidemiological rationale. Special attention is given to the association between low vitamin D status and worse postoperative outcomes.


  • Top Cited Papers
    Open Access

    Current treatment of systemic lupus erythematosus: a clinician's perspective

    by Pawlak-Buś Katarzyna, Schmidt Wiktor, Dudziec Ewa, Leszczyński Piotr

    Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Its variable course makes it difficult to standardize patient treatment. This article aims at a literature review on available drugs for treating SLE and on drugs that have shown therapeutic effects in this disease. The PubMed/MEDLINE electronic search engine was used to identify relevant studies. This review presents the current therapeutic options, new biological therapies, and combination therapies of biologics with standard immunosuppressive and immunomodulating drugs. We have also underlined the importance to implement the treat-to-target strategy aimed at reducing or discontinuing therapy with glucocorticosteroids (GCs). The awareness of the benefits and risks of using GCs helps in refining their dosage and thereby obtaining a better safety profile. The advent of biological targeted therapies, and more recently, low-molecular-weight compounds such as kinase inhibitors, initiated numerous clinical trials in SLE patients and led to the approval of two biological drugs, belimumab, and anifrolumab, for SLE treatment. Progress in the treatment of SLE was reflected in the 2019 and 2021 recommendations of the European Alliance of Associations for Rheumatology (EULAR). However, a mass of recent clinical research data requires continuous consolidation to optimize patient outcomes.


  • Open Access

    2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists

    by Katarzyna Pawlak-Buś, Piotr Leszczyński

    Systemic lupus erythematosus (SLE) is a complicated multiorgan disease and can lead to organ damage and increased risk of morbidity and mortality. The strategy of management while avoiding complications, especially caused by chronic glucocorticoid therapy, improves outcomes. Different definitions of the treatment goal in different configurations of lupus activity indexes have appeared over the years. In 2021 the definition of remission and recommendations for its achievement were published and it become a way to implement a treat-to-target strategy. The main goal of treatment has become DORIS (definition of remission in SLE) remission and the alternative LLDAS (low lupus disease activity state). Prolonging remission with clinical and immunological lupus activity restrictions and minimizing or stopping steroid doses reduced flares and damage accrual. The analysis and neutralization of poor prognosis predictive factors in lupus could be the most beneficial for less morbidity and mortality and better quality of life.


  • Open Access

    On-admission laboratory predictors for developing critical COVID-19 during hospitalization – a multivariable logistic regression model

    by Wiktor Schmidt, Barbara Jóźwiak, Zofia Czabajska, Katarzyna Pawlak-Buś, Piotr Leszczynski

    Introduction and objective: Recognition of patients with COVID-19 who will progress clinically and need respiratory support remains challenging. The aim of the study was to identify abnormalities in on-admission laboratory results that can precede progression from moderate or severe to critical...


  • Abstract reasoning is associated with corpus callosum area in neuropsychiatric systemic lupus erythematosus patients (P6.008)

    by Alicja Kalinowska-Lyszczarz, Mikolaj Pawlak, Slawomir Michalak, Wlodzimierz Paprzycki, Katarzyna Pawlak-Buś, Piotr Leszczynski, Mariusz Puszczewicz, Wojciech Kozubski